IGM Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2017
Revenue	2.13	1.07	0	0	0	Upgrade
Revenue Growth (YoY)	99.25%	-	-	-	-	Upgrade
Gross Profit	2.13	1.07	0	0	0	Upgrade
Selling, General & Admin	50.07	49.74	38.3	18.25	9.24	Upgrade
Research & Development	215.52	179.29	127.03	65.03	35.26	Upgrade
Operating Expenses	265.59	229.03	165.32	83.28	44.5	Upgrade
Operating Income	-263.46	-227.96	-165.32	-83.28	-44.5	Upgrade
Other Expense / Income	-17.72	-6.85	-0.16	-1.93	-1.37	Upgrade
Pretax Income	-245.74	-221.1	-165.16	-81.36	-43.13	Upgrade
Income Tax	0.68	0	0	0	0	Upgrade
Net Income	-246.42	-221.1	-165.16	-81.36	-43.13	Upgrade
Shares Outstanding (Basic)	52	42	33	31	9	Upgrade
Shares Outstanding (Diluted)	52	42	33	31	9	Upgrade
Shares Change	25.92%	24.09%	8.88%	241.82%	1953.40%	Upgrade
EPS (Basic)	-4.71	-5.32	-4.93	-2.65	-4.80	Upgrade
EPS (Diluted)	-4.71	-5.32	-4.93	-2.65	-4.80	Upgrade
Free Cash Flow	-204.61	-16.06	-138.23	-85.38	-47.45	Upgrade
Free Cash Flow Per Share	-3.91	-0.39	-4.13	-2.78	-5.28	Upgrade
Gross Margin	100.00%	100.00%	-	-	-	Upgrade
Operating Margin	-12369.06%	-21324.23%	-	-	-	Upgrade
Profit Margin	-11568.83%	-20683.07%	-	-	-	Upgrade
Free Cash Flow Margin	-9606.20%	-1502.25%	-	-	-	Upgrade
EBITDA	-232.05	-210.5	-157.44	-77.78	-40.8	Upgrade
EBITDA Margin	-10894.23%	-19691.30%	-	-	-	Upgrade
Depreciation & Amortization	13.69	10.6	7.72	3.58	2.33	Upgrade
EBIT	-245.74	-221.1	-165.16	-81.36	-43.13	Upgrade
EBIT Margin	-11537.00%	-20683.07%	-	-	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).